Fungemia in patients with hematologic malignancies: therapeutic effects of concomitant administration of fluconazole and granulocyte-colony-stimulating factor.
Serum (beta 1-->3)-D-glucan was elevated in 34 of 126 patients (27%) with hematologic malignancy who were clinically suspected of having a deep-seated mycosis. Although 11 patients (8.8%) were thought to have fungemia, fungi were isolated from blood culture in only 4. These results suggest that measurement of serum beta-D-glucan is useful for early diagnosis. Therapy with fluconazole (FLCZ) was effective in 9 of 11 patients (81.8%) suspected of having fungemia. Fungemia responded in 5 of 7 patients who were given granulocyte-colony-stimulating factor (G-CSF) concomitantly with FLCZ. This result suggested that administration of G-CSF with FLCZ was useful therapy for fungemia, which may occur during granulocytopenia following chemotherapy with anticancer agents.
Niitsu
N
N
First Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan.
Umeda
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000627:therapeutic use*; D016469:Fungemia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D005936:Glucans / Q000097:blood*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000150:complications; D006801:Humans; D000078224:Lenograstim; D011994:Recombinant Proteins / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000935:Antifungal Agents; D005936:Glucans; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D015725:Fluconazole